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OBJECTIVE — Wesoughttodeterminewhetheranoraldispositionindex(DIO)predictsthe
development of diabetes over a 10-year period. First, we assessed the validity of the DIO by
demonstrating that a hyperbolic relationship exists between oral indexes of insulin sensitivity
and -cell function.
RESEARCH DESIGN AND METHODS — A total of 613 Japanese-American subjects
(322 men and 291 women) underwent a 75-g oral glucose tolerance test (OGTT) at baseline, 5
years, and 10 years. Insulin sensitivity was estimated as 1/fasting insulin or homeostasis model
assessment of insulin sensitivity (HOMA-S). Insulin response was estimated as the change in
insulin divided by change in glucose from 0 to 30 min (I0–30/G0–30).
RESULTS — I0–30/G0–30 demonstrated a curvilinear relationship with 1/fasting insulin
and HOMA-S with a left and downward shift as glucose tolerance deteriorated. The conﬁdence
limits for the slope of the loge-transformed estimates included 1 for I0–30/G0–30 versus
1/fasting insulin for all glucose tolerance groups, consistent with a hyperbolic relationship.
When HOMA-S was used as the insulin sensitivity measure, the conﬁdence limits for the slope
included 1 only for subjects with normal glucose tolerance (NGT) or impaired fasting glucose
(IFG)/impaired glucose tolerance (IGT) but not diabetes. On the basis of this hyperbolic rela-
tionship,theproductofI0–30/G0–30and1/fastinginsulinwascalculated(DIO)anddecreased
fromNGTtoIFG/IGTtodiabetes(P0.001).Amongnondiabeticsubjectsatbaseline,baseline
DIO predicted cumulative diabetes at 10 years (P  0.001) independent of age, sex, BMI, family
history of diabetes, and baseline fasting and 2-h glucose concentrations.
CONCLUSIONS — The DIO provides a measure of -cell function adjusted for insulin
sensitivity and is predictive of development of diabetes over 10 years.
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T
ype 2 diabetes is characterized by
both insulin resistance and -cell
dysfunction (1). Abnormalities in
-cell function are present in high-risk
individuals long before they develop hy-
perglycemia (1). This recognition has oc-
curred in part because of a better
understanding of the ability of the -cell
to regulate its insulin response to stimuli
basedondifferencesininsulinsensitivity.
Using intravenous testing, subjects
with normal -cell function demonstrate
a hyperbolic relationship between insulin
sensitivity and insulin responses (2,3),
consistent with a classic feedback loop.
On the basis of this hyperbolic relation-
ship, the product of these two variables,
referredtoasthedispositionindex,canbe
calculated and has highlighted the inabil-
ity of the -cell to compensate for insulin
resistance in subjects at risk for diabetes
(4,5) and with higher fasting glucose lev-
els (6–8). In prospective studies, the dis-
position index declines well before
glucose levels rise into the diabetic
range (9). Thus, a low disposition index
is an early marker of inadequate -cell
compensation.
Thishyperbolicrelationshiphasbeen
demonstrated between measures of insu-
lin sensitivity and response derived from
intravenous tests (3) as well as between
the early insulin response during an oral
glucosetolerancetest(OGTT)andinsulin
sensitivity derived from intravenous test-
ing (10). However, intravenous tests are
time-consuming, expensive, and not
practical for large studies. The OGTT is
less precise (11) but simpler to perform
and is often used in large epidemiological
or intervention studies. Recently, a non-
linear function describing the relation-
ship between the oral glucose–induced
early insulin response and insulin sensi-
tivity has been used to assess -cell func-
tion in both observational (12) and
interventional studies (13). Using OGTT
measures,Retnakaranetal.(14)wereable
to show a hyperbolic relationship be-
tween insulin sensitivity (Matsuda index)
and the incremental area under the curve
insulin/glucose (incAUCins/glu) response
butnottheearlyinsulinresponse.Sakaue
et al. (15) also failed to demonstrate a hy-
perbolic relationship between OGTT-
derived insulin sensitivity and the early
insulin response. However, the latter re-
gression analysis failed to account for
measurement error in the independent
variable, which leads to an underestima-
tion of the slope (16).
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shipbetweentheearlyinsulinresponseor
the incAUCins/glu response after oral glu-
cose and surrogate measures of insulin
sensitivity were related in a hyperbolic
manner using a regression technique that
takesmeasurementerrorinbothvariables
intoaccount.Wethentestedwhetherthis
relationship exists for different glucose
tolerance categories. Finally, as we found
the relationship to be hyperbolic, we ex-
amined whether a composite measure
(oral disposition index) is associated with
the development of diabetes.
RESEARCH DESIGN AND
METHODS— TheJapaneseAmerican
Community Diabetes Study was con-
ducted in King County, Washington,
with baseline testing performed between
1983 and 1988 and follow-up examina-
tions 5 and 10 years later. The design
andmethodsusedinthisstudyhavebeen
described previously (17). The study was
approved by the local institutional review
board, and written informed consent was
obtained from each participant.
Baselineoralglucosetolerancetesting
was performed in 658 subjects; 640 sub-
jects had complete data for insulin and
glucose values at basal, 30 min, and 120
min.Tensubjectswereexcludedbecauseof
negative or zero I0–30/G0–30 (n  7) or
incAUCins/glu responses (n  3). Seventeen
subjects were excluded as outliers (see STA-
TISTICAL METHODS).Subjectswhodidnothave
diabetes at baseline (n  498) had fol-
low-up examinations and OGTTs at 5 or 6
years(5year,n448)andat10or11years
(10 year, n  398).
Study procedures and assays
A standard 75-g OGTT was performed in
the morning after a 10-h overnight fast.
Samplesweredrawnjustbeforeandat30,
60, and 120 min after ingestion of glu-
cose. Samples were collected in EDTA,
separated,andstoredat20°Cbeforebe-
ing assayed. Plasma glucose was mea-
sured by the glucose oxidase method.
Plasma insulin was measured using a
modiﬁeddouble-antibodyradioimmuno-
assay as described previously (17).
Height, weight, and abdominal circum-
ference (umbilicus) were measured three
times at each visit, and the average for
each visit was used.
Classiﬁcation of glucose tolerance
Using the 2003 American Diabetes Asso-
ciationcriteria(18),subjectswerecatego-
rized as having normal glucose tolerance
(NGT) (fasting plasma glucose [FPG]
5.56 mmol/l and 2-h plasma glucose
7.78 mmol/l), impaired glucose metab-
olism (IGM) (either impaired fasting glu-
cose [IFG]: FPG 5.56–6.99 mmol/l
and/or impaired glucose tolerance [IGT]:
2-h plasma glucose 7.78–11.10 mmol/l)
ordiabetes(FPG7.0mmol/land/or2-h
plasma glucose 11.11 mmol/l).
Calculations
Insulin sensitivity was estimated by two
methods: 1) 1/fasting insulin or 2) ho-
meostasis model assessment (HOMA) of
insulin sensitivity (HOMA-S) using the
Web-basedHOMAcalculatorfornonspe-
ciﬁc insulin (http://www.dtu.ox.ac.uk)
(19). The early insulin response was cal-
culated as the ratio of the change in insu-
lin to the change in glucose from 0 to 30
min (I0–30/G0–30). The incAUCins/glu
response was calculated by the trapezoi-
dal method from 0 to 120 min. The com-
posite measure of -cell function, which
wehavetermedtheoraldispositionindex
(DIO),wascalculatedasI0–30/G0–30
1/fasting insulin.
Statistical analysis
To determine whether the relationships
between the dependent (I0–30/G0–30
or incAUCins/glu) and independent (1/
fasting insulin or HOMA-S) variables
were consistent with a rectangular hyper-
bola (x  y  constant), we estimated
ln(I0–30/G0–30 or incAUCins/glu)a sa
linear function of ln(1/fasting insulin or
HOMA-S)usingregressionanalysis.Ifthe
hyperbolic relationship exists, the slope
oftheregressionlineshouldnotbesignif-
icantly different from 1. When error is
present in both x and y variables, the
slopethatisdeterminedbyordinaryleast-
squares regression is underestimated be-
causeitassumesallerrorintheyvariable.
The regression method we used corrects
this bias by incorporation of a factor com-
puted as the ratio of the variances of the
error in the y to x variables (16). The error
estimates for these measurements (57.1%
forI0–30/G0–30,24.9%forincAUCins/glu,
16.6%for1/fastinginsulin,and16.4%for
HOMA-S) were based on the day-to-day
coefﬁcients of variation in a group of sub-
jects with various glucose tolerance (11).
A hyperbolic relationship was presumed
if the 95% CI of the slope included 1.
The 95% CI was calculated using the
bootstrap method. Subjects were subdi-
vided for analysis by glucose tolerance
category.Theyinterceptoftheregression
line of the ln-transformed variables was
calculated, assuming a slope of 1.
Because outlying values can have
marked adverse effects on regression pa-
rameters, the data were subjected to a se-
ries of tests for inﬂuential values,
speciﬁcally, Cooks distance, DFBETA,
DFFIT, COVRatio, and HATvalue using
the R statistical procedure “inﬂuence
measures” (20). Because of the high num-
ber of data points, the critical value for
each test was set such that the  (type 1
error) was 0.002. A data point that was
identiﬁed as an inﬂuential point by any of
these tests was reviewed graphically, and
the subject was eliminated from further
analysis.
To exclude the possibility that the re-
gression is artifactual—driven by fasting
insulin and glucose appearing in both the
insulin sensitivity and I0–30/G0–30
equations—the same regression proce-
dures were performed on the data except
that the 30-min insulin values were shuf-
ﬂed using the Fisher-Yates algorithm to
remove any physiological relationship.
This shufﬂe-regression procedure was
repeated 100,000 times, and the me-
dian and 95% CIs were determined.
These simulations showed that only a
weak, positive slope resulted with wide
conﬁdence limits that did not include
1 [subjects with NGT: ln(HOMA-S)
vs. ln(I0–30/G0–30) 	 0.53 (0.13–
0.94); ln(1/fasting insulin) vs. ln(I0–30/
G0–30) 	 0.46 (0.11–0.82)].
Statistical analysis was performed us-
ing STATA (version 9.0; StataCorp, Col-
lege Station, TX). Variables that were not
normally distributed were logetransformed
to achieve a normal distribution. ANOVA
with a post hoc Scheffe correction was
performed to compare variables between
different glucose tolerance categories. Mul-
tiple logistic regression analysis was per-
formed to determine whether DIO was
independently associated with cumulative
diabetes (yes/no) at 10 years. Only subjects
without diabetes at baseline were included
in this analysis. A diagnosis of diabetes at 5
years was carried forward and included in
the cumulative 10-year incidence. The
model included ln(DIO), ln(age), sex, ln-
(BMI), ln(fasting glucose), and ln(2-h
glucose). In addition, subjects without dia-
betesatbaselineweredividedintoquintiles
of baseline DIO, and the multiple logistic
regression analysis was rerun.
To determinewhetherDIOwasabetter
predictor of diabetes than 1/fasting insulin
or I0–30/G0–30 alone, nonparametric re-
ceiver operating characteristic (ROC) curve
DIO predicts diabetes
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abetes at 10 years (no) as the outcome vari-
able. An optimal cut point for DIO was
obtained using the Youden index (maxi-
mum [sensitivity 	 speciﬁcity – 1]). P 
0.05wasconsideredstatisticallysigniﬁcant.
RESULTS— The 613 subjects were
categorized by glucose tolerance on the
basis of their fasting and 2-h plasma glu-
cose measurements (Table 1). Fasting in-
sulin, HOMA-S, and I0–30/G0–30 did
not differ between isolated IFG (iIFG),
isolated IGT (iIGT), and IFG 	 IGT
groups. Thus, these groups were com-
bined for analysis into the IGM group.
Age, BMI, and abdominal circumference
increased progressively with deteriorat-
ing glucose metabolism, whereas insulin
sensitivity and insulin responses de-
creased progressively from NGT to IGM
to diabetes (Table 1).
Hyperbolic relationship between
insulin sensitivity and insulin
responses in subjects with NGT
The 95% CI for the regression slopes in-
cluded 1 for the relationship between
ln(1/fasting insulin) and both ln(I0–30/
G0–30) (slope 0.87 [95% CI 1.13 to
0.61]) (Fig. 1A) and ln(incAUCins/glu)
(1.82 [0.97 to 0.66]). The same
analyses were performed substituting
HOMA-S for fasting insulin with similar
results [ln(I0–30/G0–30) vs. ln-
(HOMA-S): 0.91 (1.12 to 0.62]);
ln(incAUCins/glu) vs. ln(HOMA-S)
2.06 (3.38 to 0.75)]. For all re-
gressions in subjects with NGT, the
slopes included 1 in keeping with a
hyperbolic relationship.
Hyperbolic relationship between
insulin sensitivity and insulin
responses in subjects with IGM and
diabetes
InsubjectswithIGM,thecorrectedslopes
included 1 for both the relationship be-
tween ln(I0–30/G0–30) and ln(1/fasting
insulin) (0.84 [95% CI 1.05 to
0.63]) (Fig. 1B) and between ln(in-
cAUCins/glu) and ln(1/fasting insulin)
(1.27 [1.68 to 0.86]). Similar re-
sultswerefoundwhenHOMA-Swassub-
stituted for 1/fasting insulin (data not
shown). When analyzed for each individ-
ual IGM group, the relationship between
ln(I0–30/G0–30) and ln(1/fasting insu-
lin) was hyperbolic for the iIGT group
(1.15[1.43to0.87])andtheIFG	
IGTgroup(0.76[1.08to0.44])but
not for the iIFG group (0.47 [0.89 to
0.06]).Similarresultswerefoundwhen
HOMA-S was substituted for 1/fasting in-
sulin (data not shown). The slopes for the
relationship with ln(incAUCins/glu)i n -
cluded 1 for the iIFG and IFG 	 IGT
groups but not for the iIGT group using
either 1/fasting insulin or HOMA-S (data
not shown).
In those with diabetes, the corrected
slopes included 1 for the relationship
between ln(I0–30/G0–30) and ln(1/
fasting insulin) (0.76 [1.16 to
0.35]) (Fig. 1C) and between ln(in-
cAUCins/glu) and ln(1/fasting insulin)
(2.33 [3.97 to 0.69]). Use of ln-
(HOMA-S) in place of ln(1/fasting insu-
lin) resulted in a ﬂatter slope that did not
include 1 for ln(I0–30/G0–30)
(0.55 [0.97 to 0.12]) and a slope
that did include 1 but had a very wide
CIforln(incAUCins/glu)(2.74[5.82to
0.35]).
The hyperbolic curves demonstrated
a shift to the left and downward from
NGT to IGM to diabetes (I0–30/G0–30
versus1/fastinginsulin)(Fig.1D).Similar
shifts were seen when HOMA-S or in-
cAUCins/glu was used. This decrease in
-cell function is best evaluated by exam-
ination of the y intercepts for the ln-ln
relationships. These intercepts decreased
from NGT (mean 
 SD 0.53 
 0.63) to
IGM (0.09 
 0.61) to diabetes (1.36 

0.99) for ln(I0–30/G0–30) versus ln(1/
fasting insulin). Similar decreases were
seen for ln(I0–30/G0–30) versus ln-
(HOMA-S) (NGT 9.12 
 0.63, IGM
8.66 
 0.61, and diabetes 7.13 
 1.04),
ln(incAUCins/glu) versus ln(1/fasting insu-
lin)(NGT0.82
0.62,IGM0.39
0.52,
and diabetes 1.15 
 0.98), and ln(in-
cAUCins/glu) and ln(HOMA-S) (NGT
9.42 
 0.62, IGM 8.97 
 0.52, and dia-
betes 7.34 
 1.05) (P  0.005 for all
comparisons).
On the basis of the hyperbolic rela-
tionship between I0–30/G0–30 and
1/fastinginsulin,theproductofthesetwo
variables (DIO) was computed as a com-
positemeasureof-cellfunction.DIOde-
creased progressively from NGT to IGM
to diabetes (P  0.001 for all compari-
sons) (Fig. 2A). Similar results were ob-
tained when DIO was calculated using
HOMA-Sinsteadof1/fastinginsulin(data
not shown). When DIO was compared
among the three IGM groups (iIFG me-
dian 1.15 [interquartile range 0.96], iIGT
1.07 [0.82], and IFG 	 IGT 0.89[0.77]
mM
1), DIO was lower in the IFG 	 IGT
group than in the iIFG group (P  0.01)
or iIGT group (P  0.051) but did not
differ signiﬁcantly between the iIFG and
iIGT groups.
Table 1—Subject characteristics by glucose tolerance category
NGT iIFG iIGT IFG 	 IGT IGM Diabetes
n 244 60 118 76 254 115
Age (years) (mean 
 SD) 48.6 
 11.9 56.4 
 10.7 54.0 
 11.5 59.1 
 9.5§ 56.1 
 10.9* 61.1 
 7.4*
Sex (female/male) 120/124 20/40 79/39† 23/53§ 122/132 49/66
BMI (kg/m
2) 23.5 
 0.2 24.7 
 0.3 23.7 
 0.3 25.8 
 0.4§ 24.6 
 0.2* 25.7 
 0.3*
Abdominal circumference (cm) 84.0 
 0.51 87.7 
 0.8 85.5 
 0.9 90.0 
 0.9§ 87.6 
 0.5* 91.0 
 0.8*
FPG (mmol/l) 4.89 (0.58) 5.72 (0.39) 5.06 (0.50)† 5.89 (0.39)§ 5.56 (0.72)* 7.56 (3.33)*
2-h plasma glucose (mmol/l) 6.22 (1.44) 6.94 (1.08) 8.69 (1.11)† 9.19 (1.78)‡§ 8.47 (1.56)* 15.17 (8.56)*
Fasting insulin (pmol/l) 66 (36) 81 (48) 69 (48) 78 (51) 78 (54)* 102 (96)*
HOMA-S 81.9 (45.2) 63.9 (36.4) 79.2 (50.2) 65.8 (38.8) 70.7 (46.9)* 47.0 (44.7)*
I0–30/G0–30 (pmol/mmol) 105.7 (102.5) 100.2 (101.9) 81.7 (92.6) 77.9 (65.0) 80.9 (86.5)* 29.9 (41.4)*
incAUCins/glu (pmol/mmol) 148.6 (138.6) 138.5 (146.5) 104.3 (83.8)† 105.6 (77.8)‡ 113.3 (90.8)* 33.8 (49.0)*
Dataarereportedasmean
SEMormedian(interquartilerange)unlessotherwisespeciﬁed.*P0.001NGTversusIGMversusdiabetes;†iIFGversusiIGT,‡iIFG
versus IFG 	 IGT, §iIGT versus IFG 	 IGT, P  0.05.
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development of diabetes over
10 years
Subjects who progressed to diabetes over
the 10-year follow-up period (“progres-
sors”: n  9 with baseline NGT and n 
84 with baseline IGM) were compared
with those who did not progress (“non-
progressor”: n  235 with baseline NGT
andn170withbaselineIGM).Baseline
DIO was signiﬁcantly lower in the pro-
gressors versus the nonprogressors (NGT
median0.90[interquartilerange0.40]vs.
1.72 [1.42] mM
1, P  0.05; IGM 0.85
[0.57]vs.1.12[0.94]mM
1,P0.001).
Therelationshipbetweeninsulinsensitiv-
ity and insulin response at baseline was
shifted downward and to the left in the
progressors compared with the nonpro-
gressors (Fig. 2B).
WeexaminedwhetherDIOwasanin-
dependent predictor of the development
of diabetes over time. In subjects who did
nothavediabetesatbaseline,ahigherDIO
was associated with a decreased risk of
diabetes at 10 years (odds ratio [OR] 0.40
[95%CI0.25–0.66],P0.001)afterad-
justmentforln(age),sex,ln(BMI),ln(fast-
ing glucose), and ln(2-h glucose). Family
history added to the model was a weak
independent predictor of diabetes (1.79
[1.04–3.09], P  0.03) but did not
change the signiﬁcance of DIO (0.41
[0.25–0.68], P  0.001). Similar results
were obtained when both family history
and ln(triglycerides) were added to the
model. When ln(1/fasting insulin) and
ln(I0–30/G0–30) were included in the
basicmodelinplaceofln(DIO),bothwere
independent predictors of diabetes at the
10-year follow-up: ln(1/fasting insulin)
0.32 [0.14–0.73] and ln(I0–30/G0–30)
0.41 [0.25–0.68]. Similar results were
obtained when HOMA-S was used to
computeDIO(datanotshown).Whenthe
analysis was restricted to subjects with
NGTatbaseline,DIOwasstillanindepen-
dent predictor of diabetes (0.24 [0.06–
0.88], P  0.03).
When the multiple logistic regression
analysis was rerun using quintiles of DIO
(categorical variables coded as dummy
variables), the risk for diabetes decreased
as DIO increased (versus quintile 1 [low-
est DIO]: quintile 2 OR 0.63 [95% CI
0.32–1.25], P  0.19; quintile 3 0.40
[0.18–0.90], P  0.03; quintile 4 0.39
[0.17–0.94], P  0.04; and quintile 5
[highest DIO] 0.14[0.05–0.45], P 
0.001). The number of subjects who de-
veloped diabetes over the 10 years de-
creasedastheDIOquintileincreased(Fig.
2C).
ROC curve analysis was performed to
determine whether the composite mea-
sure DIO was better at predicting protec-
tionfromdiabetescomparedwithI0–30/
G0–30 or 1/fasting insulin alone. The
area under the ROC curve was highest
usingDIO(0.86[95%CI0.82–0.89]),in-
termediate for I0–30/G0–30 (0.78
[0.74–0.82]), and lowest for 1/fasting in-
sulin (0.65 [0.60–0.70]). The area under
the ROC curve for DIO was signiﬁcantly
higher than that for the other two vari-
ables (P  0.001 for each) (Fig. 2D). The
best predictor for remaining without dia-
Figure1—Thecomputedslopes(——)and95%CIsfortheslopes(– – –)forln(I0–30/G0–30)versusln(1/fastinginsulin)areplottedforsubjects
with NGT (slope 0.87 [95% CI 1.13 to 0.61]) (A), IGM (0.84 [1.05 to 0.63]) (B), and diabetes (DM) (0.76 [1.16 to 0.35]) (C).
D: The hyperbolic curves for NGT, IGM, and diabetes, assuming a slope of 1, are plotted for I0–30/G0–30 versus 1/fasting insulin.
DIO predicts diabetes
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59.3% and speciﬁcity of 79.6%).
CONCLUSIONS — A hyperbolic re-
lationship between insulin sensitivity and
responsesusingintravenousmeasures(3)
has been widely accepted. This study
demonstrates that measures of insulin
sensitivity and response derived from an
OGTT are also compatible with a hyper-
bolic association and that this relation-
ship is present not only in subjects with
NGT but also in subjects with IGM and
diabetes. Importantly, the existence of
this relationship allows calculation of a
DIO,whichwaspredictiveoffuturedevel-
opmentofdiabetesaboveandbeyondtra-
ditionalriskfactors,suchasfamilyhistory
and fasting and 2-h glucose levels. The
DIO as a composite measure was a better
predictor for diabetes than either I0–30/
G0–30 or 1/fasting insulin alone.
Our ﬁnding that the relationship be-
tween insulin sensitivity and insulin re-
sponse based on OGTT measures is
shifted downward and to the left as glu-
cose tolerance deteriorates is consistent
with previous work using intravenous
tests (6,21). With the use of intravenous
measures, the disposition index was
lower at baseline and declined further in
those whose glucose metabolism deterio-
rated over time (9,21,22). Our current
ﬁndings extend use of this approach to
measure -cell function using OGTT-
derived measures. Importantly, we have
shown that the DIO was inversely corre-
lated with the risk of future diabetes.
Thus, the DIO may be useful to help iden-
tify subjects in large epidemiological
studies who have an increased risk of de-
veloping diabetes.
The statistical methodology for as-
sessmentofthishyperbolicrelationshipis
critical when both the x and y variables
are measured with error, as the slope will
be underestimated if measurement error
in the independent variable is not ac-
counted for (23). The absence of a hyper-
bolic relationship between these same
OGTT measures in a previously pub-
lished study (15) may have been due to
thisissue.AlthoughRetnekaranetal.(14)
did account for error estimates in both
variables, the slopes for the relationships
between I0–30/G0–30 and measures of
insulin sensitivity (1/HOMA for insulin
resistance and the Matsuda index) were
1( 1.61 and 1.60, respectively)
and because of the wide CIs that included
0werenotconsideredtobehyperbolic.In
contrast,wefoundthattheslopesforsub-
jects with NGT for the log-relationships
between I0–30/G0–30 and 1/fasting in-
sulin (slope  0.87) or HOMA-S
(slope  0.91) were slightly 1, but
theCIstillincluded1,consistentwitha
hyperbolicrelationship.Differencesinre-
sults between our study and that by Ret-
nakaran et al. could be due to differences
in error estimates, as the slopes are quite
sensitive to changes in error estimates. Of
note, our results are consistent with the
slope estimates for the log-relationship
betweentheacuteinsulinresponsetoglu-
cose and the insulin sensitivity index (SI)
derived from a frequently sampled intra-
venous glucose tolerance test (slope 
0.97) (3) or between I0–30/G0–30
and SI (slope  0.86) (10).
The strengths of this study include
the large number of subjects and the lon-
gitudinal study design. However, we
failed to show a hyperbolic relationship
Figure 2—A: The DIO (I0–30/G0–30  1/fasting insulin) decreases from NGT to IGM to diabetes (DM) (median [interquartile range]). B: The
logarithmic means for baseline I0–30/G0–30 and 1/fasting insulin values are plotted for subjects with NGT (f and  ) and IGM (F and E)a s
nonprogressors (f and F) and progressors (  and E) relative to the hyperbolic curves. Progressors had lower -cell function at baseline. C: The
numberofsubjectswhodevelopeddiabetesoverthe10-yearfollow-upperiodbyquintilesofbaselineDIO.D:ROCcurvescomparingabilityofbaseline
I0–30/G0–30 (dotted line), 1/fasting insulin (dashed line), and DIO (solid line) to predict cumulative diabetes at 10 years.
Utzschneider and Associates
DIABETES CARE, VOLUME 32, NUMBER 2, FEBRUARY 2009 339for some regressions when the iIFG and
iIGT groups were examined separately. It
is possible that glucose tolerance in these
subpopulations fails to follow a hyper-
bolic relationship, although it seems un-
likely because when they are combined
the hyperbolic relationship is present. In
the group with diabetes, the log-
relationshipsbetweenI0–30/G0–30and
insulin sensitivity measures were ﬂatter
and did not include 1 when HOMA-S
was used. This may reﬂect the much
broader range of glucose tolerance (and
fasting glucose levels) in this group. Fi-
nally, the CIs for the slopes using the in-
cAUCins/glu ratio, although including 1,
were much wider and thus less reliable.
Other limitations include the fact that we
excluded 17 subjects (2.7%) with outlier
data from this analysis, as outliers can
have a disproportionate effect on regres-
sion analysis. Finally, this study was per-
formed in Japanese Americans, and, thus,
we cannot generalize the conclusions to
other ethnic populations, although it is
likely that the same physiological feed-
back processes would occur in other eth-
nic groups.
Therearelimitationstoapplicationof
the DIO that need to be kept in mind. In
particular, because of the increased vari-
ability of OGTT measures compared with
intravenous testing, the DIO will be more
variable and, hence, appropriately large
sample sizes will be needed. Second, it
cannot be assumed that all measures of
insulin sensitivity or response will fol-
low a hyperbolic pattern and thus sim-
ply multiplying any two measures
together without ﬁrst demonstrating a
hyperbolic function is not appropriate.
Also, it should be kept in mind that the
compensatory insulin response in-
cludesbothchangesininsulinsecretion
as well as adaptations in hepatic insulin
extraction (24) and changes in incretin
hormone responses that may modulate
both insulin secretion and hepatic insu-
lin extraction (25).
In summary, we have demonstrated
that use of OGTT-derived measures of in-
sulin response and insulin sensitivity can
delineate differences in -cell function
between glucose tolerance categories.
Furthermore,thecompositemeasureDIO
can be used to assess -cell function and
was independently associated with fu-
ture diabetes risk. Thus, the disposition
index approach using these speciﬁc
measures offers a way to assess -cell
function using an OGTT and could be
used to identify subjects with poor
-cell function for intervention trials
andtoassesstheimpactofinterventions
in large clinical studies.
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